Evolus

98 articles about Evolus

• 

  BioSpace Hotbed Report: The Surging Tide of Biotech Beach

  2/5/2019

  The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.
• 

  FDA Action Alert: Sanofi, Alkermes, Andor and More

  1/28/2019

  Here’s a look at this week’s calendar for decisions coming down from the U.S. Food and Drug Administration (FDA). 

• SetPoint Medical Appoints Murthy Simhambhatla as President and Chief Executive Officer

  8/13/2018

  Industry veteran brings biopharma and medical device company leadership experience as SetPoint advances its proprietary bioelectronic medicine platform.

• Evolus Reports Second Quarter 2018 Financial Results

  8/2/2018

  Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today reported financial results for the second quarter ended June 30, 2018.

• Evolus Announces Early Resubmission to the FDA of Its Biologics License Application for DWP-450

  8/2/2018

  Evolus, Inc., a company dedicated to aesthetic medicine, announced that today it is resubmitting its Biologics License Application for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the U.S Food and Drug Administration

• 

  FDA Rejects Evolus’ Botox Knockoff for Now

  5/16/2018

  The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Evolus for its Biologics License Application (BLA) for DWP-450 (prabotulinumtoxinA), a drug to treat frown lines similar to Allergan’s Botox.
• 

  Three Companies with FDA Decisions in the Next Week

  5/15/2018

  There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
• 

  Hiring Roundup of Biotech Leaders

  5/13/2018

  Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies.

• Evolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer

  5/7/2018

  Evolus, Inc. announced that its board of directors has named David Moatazedi as President and Chief Executive Officer.

• 

  8 Biotech Companies with Upcoming Catalysts

  3/14/2018

  Here’s a look at eight biopharma companies with upcoming catalysts.

• Evolus Announces Closing of Initial Public Offering of Common Stock

  2/12/2018

  Evolus raised approximately $60M in gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses.

• Evolus Announces Pricing of Initial Public Offering of Common Stock

  2/8/2018

  Evolus has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

• 

  SoCal's Evolus Files for $75M IPO

  1/9/2018

  Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers for the offering.

• Medytox Files Citizen Petition with FDA Requesting Investigation of Application for Botulinum Drug Product

  12/5/2017

  False statements about a botulinum toxin strain and concerns about integrity of data and the impact on patient safety are at the core of a Citizen Petition filed today asking the U.S. Food and Drug Administration (FDA) not to approve the neurotoxin product made by Daewoong Pharmaceuticals Co., Ltd. that is the subject of a Biological Product Application (BLA) submitted by Evolus Inc.

• Evolus Announces Health Canada Acceptance for Review of the New Drug Submission for PrabotulinumtoxinA

  10/27/2017

  Evolus received confirmation from Health Canada that the NDS for prabotulinumtoxinA, a 900 kilodalton Botulinum toxin Type A, for the treatment of adult patients with glabellar lines, also known as "frown lines" between the eyebrows, has been accepted for review.

• Evolus Announces Presentations Of Phase II And Phase III Data Of Prabotulinumtoxina

  10/10/2017

• Evolus Announces EMA Acceptance For Review Of The Marketing Authorization Application For DWP-450 Neuromodulator

  7/20/2017

• Evolus Announces FDA Acceptance For Review Of The Biologics License Application For DWP-450 Neuromodulator

  7/19/2017